A Phase 3 interventional study of Cariprazine and Placebo in Major Depressive Disorder, sponsored by AbbVie. Completed at 112 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 9th largest by enrollment, is one of 7 that started in 2018, is one of 31 in phase 3, and was the 48th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 752 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 442 across the 53 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
1 of the studies in Depressive Disorder, Major by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07276997AbbVieA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Depressive Disorder, Major by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine matching placebo capsules, orally, once daily in addition to their ongoing antidepressant therapy (ADT) \[same antidepressant and dose of ADT they were on at the Baseline\] during the Double-blind Treatment Period, up to Week 6.
Drug: Placebo · Drug: Antidepressant Therapy (ADT)
Cariprazine 1.5 mg capsules, orally, once daily in addition to their ongoing ADT (same antidepressant and dose of ADT they were on at the Baseline) during the Double-blind Treatment Period, up to Week 6.
Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)
Cariprazine 1.5 mg capsules, orally, once daily for 2 weeks starting at the Baseline, titrated to 3.0 mg capsules, orally, once daily from Week 2 through Week 6 in addition to their ongoing ADT (same antidepressant and dose of ADT) during the Double-blind Treatment Period, up to Week 6.
Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)
Cariprazine supplied in capsules
Also known as: VRAYLAR®
Placebo supplied in capsules
ADT as prescribed by the physician per standard of care in clinical practice.
Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) was used for analyses.
Time frame: Baseline and Week 6
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score
The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses.
Time frame: Baseline and Week 6
| Milestone | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| Started | 250 | 250 | 251 |
| Modified intent-to treat (mitt) population | 249 | 250 | 251 |
| Completed | 235 | 233 | 226 |
| Not completed | 15 | 17 | 25 |
| Withdrew: Adverse event | 6 | 9 | 13 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 4 | 6 |
| Withdrew: Protocol deviation | 1 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 3 | 1 |
| Withdrew: Reason not specified | 1 | 0 | 1 |
| Milestone | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| Started | 242 | 242 | 242 |
| Completed | 240 | 240 | 238 |
| Not completed | 2 | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 2 |
The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) was used for analyses.
| score on a scale | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score | -13.4 ± 0.70 | -13.8 ± 0.69 | -14.8 ± 0.70 |
The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses.
| score on a scale | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score | -1.4 ± 0.09 | -1.4 ± 0.09 | -1.6 ± 0.09 |
Collected over First dose of study drug until 30 days after the last dose of study drug (up to 12 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + ADT | 1/250 (0.4%) | 2/250 (0.8%) | 54/250 (21.6%) |
| Cariprazine 1.5 mg/Day + ADT | 0/250 (0%) | 3/250 (1.2%) | 70/250 (28%) |
| Cariprazine 3 mg/Day + ADT | 0/251 (0%) | 1/251 (0.4%) | 85/251 (33.9%) |
| Event | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/250 | 0/250 | 0/251 |
| DEATHGeneral disorders | 1/250 | 0/250 | 0/251 |
| ANIMAL BITEInjury, poisoning and procedural complications | 0/250 | 1/250 | 0/251 |
| FALLInjury, poisoning and procedural complications | 0/250 | 1/250 | 0/251 |
| FIBULA FRACTUREInjury, poisoning and procedural complications | 0/250 | 1/250 | 0/251 |
| LIGAMENT SPRAINInjury, poisoning and procedural complications | 0/250 | 1/250 | 0/251 |
| SUICIDE ATTEMPTPsychiatric disorders | 0/250 | 1/250 | 0/251 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/250 | 0/250 | 1/251 |
| Event | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT |
|---|---|---|---|
| AKATHISIANervous system disorders | 9/250 | 19/250 | 29/251 |
| HEADACHENervous system disorders | 27/250 | 24/250 | 27/251 |
| INSOMNIAPsychiatric disorders | 9/250 | 16/250 | 25/251 |
| SOMNOLENCENervous system disorders | 11/250 | 12/250 | 17/251 |
| NAUSEAGastrointestinal disorders | 10/250 | 14/250 | 16/251 |
Safety Population included all participants in the randomized population who took ≥1 dose of double-blind investigational product.
| Age, Continuous(years) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| Mean | 46.2 ± 12.12 | 45.0 ± 12.95 | 45.8 ± 12.45 | 45.7 ± 12.51 |
| Sex: Female, Male(Participants) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| Female | 191 | 185 | 197 | 573 |
| Male | 59 | 65 | 54 | 178 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| Hispanic or Latino | 30 | 38 | 34 | 102 |
| Not Hispanic or Latino | 220 | 212 | 217 | 649 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 |
| Asian | 4 | 0 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 29 | 32 | 22 | 83 |
| White | 217 | 216 | 221 | 654 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Montgomery-Asberg Depression Rating Scale (MADRS) Total Score(score on a scale) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| Mean | 32.99 ± 4.789 | 32.00 ± 4.246 | 32.25 ± 4.688 | 32.41 ± 4.593 |
| Clinical Global Impression-Severity (CGI-S) Scale Score(score on a scale) | Placebo + ADT | Cariprazine 1.5 mg/Day + ADT | Cariprazine 3 mg/Day + ADT | Total |
|---|---|---|---|---|
| Mean | 4.67 ± 0.599 | 4.61 ± 0.586 | 4.65 ± 0.654 | 4.64 ± 0.614 |
Showing the first 100 of 112 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Nov 2018 to primary completion in Sep 2021, 33 months.
Results were first posted in Sep 2022, 1 year after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 33 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine